Anti-hepatic-fibrosis traditional Chinese medicinal decoction

Abstract

The invention relates to the field of pharmaceutical formulations, in particular to an anti-hepatic-fibrosis traditional Chinese medicinal decoction. The anti-hepatic-fibrosis traditional Chinese medicinal decoction is characterized by comprising, by weight, 17-22 parts of silybum marianum, 13-17 parts of prince's-feather fruits, 17-22 parts of desmodium, 3-7 parts of abrus herbs, 13-17 parts of urena procumbens, 17-22 parts of the root of tubeflower duchmans pipe, 17-22 parts of polygonum polystachyum, 13-17 parts of polygonum capitatum, 17-22 parts of Chinese starjasmine stems, 22-28 parts of ground beetles, 13-17 parts of lomatogonium rotatum, 3-7 parts of leeches, 13-17 parts of giant knot weeds, 8-12 parts of the root of Chinese thorowax, 8-12 parts of peach kernels, 5-10 parts of Chinese honeylocust spines, 13-17 parts of roasted turtle shells, 8-12 parts of chicken's gizzard-membranes, 8-12 parts of astragalus membranaceus and 17-22 parts of madder. The raw materials are soaked in water, and dregs are removed after decoction to obtain a filtrate. The anti-hepatic-fibrosis traditional Chinese medicinal decoction can eliminate inflammatory cells and inflammatory media of hepatic inflammations and has remarkable curative effect on hepatic fibrosis caused by hepatitis virus infection.

Description

technical field [0001] The invention relates to a Chinese patent medicine preparation, in particular to a Chinese medicine decoction for resisting liver fibrosis. Background technique [0002] As we all know, liver fibrosis is a common pathological process in which many chronic pathogenic factors act on the liver and cause excessive deposition of extracellular matrix. The pathogenic factors cause liver oxidative stress and cytokine production are the initiating links of liver fibrosis. Long-term application of nucleoside antiviral drug lamivudine can improve liver inflammation and reduce or prevent the progression of liver fibrosis; retinoic acid can inhibit hepatic stellate cell procollagen I, II, IV, fibronectin Synthesis of protein and mucin and promotion of collagenase secretion by monocytes, inhibition of HSC activation, and reversal of activated HSC to a quiescent state, thereby reducing the synthesis of extracellular matrix. However, long-term use may have toxic effec...

AI Technical Summary

Problems solved by technology

Long-term application of nucleoside antiviral drug lamivudine can improve liver inflammation and reduce or prevent the progression of liver fibrosis; retinoic acid can inhibit hepatic stellate cell procollagen I, II, IV, fibronectin Synthesis of protein and mucin and promotion of collagenase secretion by monocytes, inhibition of HSC activation, and reversal of activated HSC to a quiescent state, thereby reducing the synthesis of extracellular matrix, however, long-term use may have toxic effects on the liver

A variety of drugs have certain effects on the treatment of liver fibrosis, such as IFN-γ. Although it has been observed to have a good anti-fibrosis effect, its side effects on the body limit its application, and the high cost also makes the general income discouraged

Images